Cure My Disease

Don't miss your cure!

Log in / Sign up

← Back to home

Exelixis

Clinical trials sponsored by Exelixis, explained in plain language.

Exelixis EXEL NASDAQ

Oncology-focused biopharmaceutical company developing cancer treatments.

Trade on eToro (ad)

Not investment advice. Company information is shown for context only. Clinical trials frequently fail.

Trials to join now! 7 Not yet recruiting 2 Not yet finished but already full! 7 Completed 1 Terminated 2

New combo therapy shows promise for tough lung cancer cases

Disease control Completed

This study tested a drug called cabozantinib, either alone or with another drug (erlotinib), in 92 people with advanced non-small cell lung cancer whose cancer had worsened after erlotinib treatment. The goal was to find a safe dose and see if the combination could shrink tumors.…

Phase: PHASE1, PHASE2 • Sponsor: Exelixis • Aim: Disease control

Last updated Jun 27, 2026 08:10 UTC